Background {#Sec1}
==========

G protein coupled receptors (GPCRs), one of the largest protein families within the human genome, play an important role in several physiological and pathophysiological processes (Wise et al. [@CR51]; Foord et al. [@CR9]; Jacoby et al. [@CR13]). In general, the two-state model of GPCR activation suggests that GPCRs can exist in two different states, the inactive "R" and active "R\*" state (Schütz and Freissmuth [@CR38]; Lefkowitz et al. [@CR19]; Leff [@CR17]; Seifert and Wenzel-Seifert [@CR40]). These two different conformations were confirmed by crystal structures of the inactive and active state of the β~2~-adrenergic receptor (Cherezov et al. [@CR4]; Rosenbaum et al. [@CR29]; Rasmussen et al. [@CR28]). Ligands, addressing GPCRs, can be classified as inverse agonists, neutral antagonist or agonists (Seifert and Wenzel-Seifert [@CR40], [@CR41]). It is assumed that inverse agonists stabilize the inactive, whereas agonists stabilize the active state of GPCRs (Seifert and Wenzel-Seifert [@CR40], [@CR41]). The histamine H~3~ receptor (H~3~R), identified in the early 1980s, is one of four histamine receptor subtypes and belongs to the aminergic GPCRS (Hill et al. [@CR11]; Lovenberg et al. [@CR22]; Leurs et al. [@CR20]; Parsons and Genellin [@CR27]). The H~3~R regulates the release of the endogenous histamine and other neurotransmitters in the nervous system and is involved in important physiological processes, e.g. cognition, eating-behaviour and the sleep-wake cycle (Leurs et al. [@CR20]). For the hH~3~R, a large number of ligands is known (Sasse et al. [@CR30]; Stark et al. [@CR45]; Schnell and Seifert [@CR36]; Strasser et al. [@CR48]; Seifert et al. [@CR42]). However, thioperamide is a standard inverse agonist at the hH~3~R (Arrang et al. [@CR2]; Schnell and Seifert [@CR36]). Some GPCRs, showing constitutive activity, change its conformation from the inactive into the active state in absence of an agonist (Seifert and Wenzel-Seifert [@CR40], [@CR41]). It was shown that the hH~3~R and the highly related hH~4~R exhibit constitutive activity (Morisset et al. [@CR24]; Schneider et al. [@CR35]; Schnell et al. [@CR37]). Experimental studies revealed that sodium ions can act as an allosteric modulator and stabilize the inactive conformation of a GPCR (Seifert and Wenzel-Seifert [@CR40], [@CR41]). Experimental studies revealed that only distinct GPCRs are sensitive for sodium ions, whereas other GPCRs are insensitive for sodium ions. The neurotensine receptors (Martin et al. [@CR23]), the D~2~ (Neve [@CR25]; Schetz [@CR31]; Ericksen et al. [@CR7]) for example, are sodium sensitive. Within the family of the histamine receptors, the hH~3~R is sodium sensitive (Schnell and Seifert [@CR36]) whereas the highly related hH~4~R is sodium insensitive (Schneider and Seifert [@CR34]). The corresponding allosteric sodium ion binding site is located between TM II, TM III and TM VII near to the highly conserved Asp^2.50^, as was shown recently with the crystal structure of the human adenosine A~2A~ receptor (hA~2A~R) (Liu et al. [@CR21]) or the δ-opioid receptor (Fenalti et al. [@CR8]). The location of the allosteric sodium binding site was also supported by mutagenesis of the highly conserved Asp^2.50^ into the neutral alanine (Neve et al. [@CR26]; Schetz and Sibley [@CR32]) or asparagine (Ceresa and Limbird [@CR3]; Schnell and Seifert [@CR36]). This is supported by experimental results at hH~3~R, where the Asp^2.50^Asn mutant was found to partially mimic the effect of high sodium chloride concentrations by suppressing constitutive activity (Schnell and Seifert [@CR36]). With MD studies the binding pathway of a sodium ion into the allosteric sodium binding site of the D~2~ receptor (Selent et al. [@CR43]) and the μ-opioid receptor (Yuan et al. [@CR52]) were observed.

During the last decades, several theoretical models were established to explain receptor function quantitatively (Leff [@CR17]; Leff et al. [@CR18]; Christopoulos and Kenakin [@CR5]; Kenakin [@CR14]; Langmead and Christopoulos [@CR16]; Kenakin [@CR15]). Those basic concepts can be extended to describe ion-sensitivity of GPCRs. Within a previous study of Schnell and Seifert ([@CR36]), the influence of NaCl concentration onto the concentration response curves of the endogenous histamine and the inverse agonist thioperamide onto the hH~3~R were investigated (Figure [1](#Fig1){ref-type="fig"}). Within the present study, we developed a set of equations, describing constitutive activity and the different ligand-receptor equilibra in presence or absence of sodium ions. Furthermore, we used the experimental data, published by Schnell and Seifert ([@CR36]) previously (Figure [1](#Fig1){ref-type="fig"}) for determination of the equilibrium constants, described by the set of equations, mentioned above, e.g. constants regard to constitutive activity, binding of a sodium ion to the receptor, and binding of histamine or thioperamide to the hH~3~R in absence or presence of sodium ions. Furthermore, MD simulations of several inactive thioperamide-Na^+^-hH~3~R-complexes were performed. These simulations showed that thioperamide can bind into the orthosteric site of hH~3~R in presence or absence of the Na^+^ in the allosteric pocket, resulting in different binding modes of thioperamide.Figure 1**Sodium sensitivity oh hH** ~**3**~ **R. A**, Structures of histamine and thioperamide. **B**, Influence of sodium ions onto the hH~3~R, determined in the steady state GTPase assay. (Figure was adopted from Schnell and Seifert ([@CR36]).

Methods {#Sec2}
=======

Equations {#Sec3}
---------

For the quantitative description of the sodium sensitivity of the hH~3~R, ten different mass action laws describing the formation of different ligand-receptor complexes were included. Equation ([1](#Equ1){ref-type=""}) takes into account the experimentally observed constitutive activity of the ligand free receptor according to the equilibrium *R* ⇌ *R\**:$$\documentclass[12pt]{minimal}
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Therein, *R\** represents the ligand- and sodium free- active receptor and *R* the ligand- and Na^+^- free inactive receptor.

Additionally, distinct Na^+^-receptor equilibriums have to be considered: Equation ([2](#Equ2){ref-type=""}) describes the equilibrium between the inactive receptor *R* and the inactive receptor containing a sodium ion in the orthosteric ligand binding pocket denoted by *A*^*ortho*^*R* according to *A* + *R* ⇌ *A*^*ortho*^*R*. Therein, the concentration of sodium chloride *A* is considered to be equal to the overall concentration *A*~*0*~ of sodium chloride, because of the much smaller concentration of the receptor species. This approximation holds also for the ligands thioperamide (*B*) and histamine (*C*).$$\documentclass[12pt]{minimal}
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In general, it has to be taken into account (equation [3](#Equ3){ref-type=""}) that sodium ions are able to bind into the orthosteric binding pocket of the active receptor establishing the complex *A*^*ortho*^*R\** according to *A* + *R\** ⇌ *A*^*ortho*^*R\**:$$\documentclass[12pt]{minimal}
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Based on experimental studies, it is suggested that a sodium ion *A* can bind from its orthosteric into its allosteric binding pocket to form the species *A*^*allo*^*R* according to *A*^*ortho*^*R* ⇌ *A*^*allo*^*R*. This fact is considered in equation [4](#Equ4){ref-type=""}.$$\documentclass[12pt]{minimal}
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Additionally in the presence of thioperamide marked by *B*, the following equations ([5](#Equ5){ref-type=""}, [6](#Equ6){ref-type=""}, [7](#Equ7){ref-type=""}) have to be considered. Thioperamide *B* can bind into the orthosteric ligand binding site of the inactive receptor and a corresponding thioperamide-receptor complex *BR* is formed (equation [5](#Equ5){ref-type=""}) according to *B* + *R* ⇌ *BR*.$$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ {K}_4=\frac{ BR}{B_0\cdot R} $$\end{document}$$

There, *B*~*0*~ represents the total concentration of thioperamide. Furthermore, it has to be taken into account that thioperamide may also be able to bind into the orthosteric ligand binding site of the active receptor (equation [6](#Equ6){ref-type=""}) and a corresponding active thioperamide-receptor complex *BR\** is formed according to *B* + *R\** ⇌ *BR*^*\**^.$$\documentclass[12pt]{minimal}
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Next, it has to be considered that thioperamide binds into the orthosteric binding site when a sodium ion is bound into the allosteric binding site of the inactive receptor (equation [7](#Equ7){ref-type=""}) forming the complex *BA*^*allo*^*R* according to *B* + *A*^*allo*^*R* ⇌ *BA*^*allo*^*R*.$$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ {K}_6=\frac{B{A}^{allo}R}{B_0\cdot {A}^{allo}R} $$\end{document}$$

In case that histamine *C* is present, the equations ([8](#Equ8){ref-type=""}, [9](#Equ9){ref-type=""}, [10](#Equ10){ref-type=""}) have to be taken into account. In general it should be considered that histamine *C* is able to bind into the orthosteric ligand binding site of the inactive receptor (equation [8](#Equ8){ref-type=""}) and a corresponding histamine-receptor complex *CR* is formed according to *C* + *R* ⇌ *CR*:$$\documentclass[12pt]{minimal}
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                \begin{document}$$ {K}_7=\frac{ CR}{C_0\cdot R} $$\end{document}$$where *C*~*0*~ describes the total concentration of histamine. Furthermore, it has to be taken into account that histamine binds into the orthosteric ligand binding site of the active receptor (equation [9](#Equ9){ref-type=""}) and a corresponding active histamine-receptor complex *CR\** is formed according to *C* + *R\** ⇌ *CR*^*\**^:$$\documentclass[12pt]{minimal}
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Additionally, it has to be expected that histamine binds into the orthosteric binding site when a sodium ion is bound into the allosteric binding site (equation [10](#Equ10){ref-type=""}) of the inactive receptor *CA*^*allo*^*R* at the same time according to *C* + *A*^*allo*^*R* ⇌ *CA*^*allo*^*R*:$$\documentclass[12pt]{minimal}
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It is suggested that sodium ions are not able to bind into the allosteric binding site of the active receptor (Liu et al. [@CR21]). Therefore, the corresponding complexes are not considered within the presented system of equations. Once more, it should be mentioned that the overall concentrations of sodium chloride, thioperamide and histamine (eqs. [2](#Equ2){ref-type=""}, [3](#Equ3){ref-type=""}, [4](#Equ4){ref-type=""}, [5](#Equ5){ref-type=""}, [6](#Equ6){ref-type=""}, [7](#Equ7){ref-type=""}, [8](#Equ8){ref-type=""}, [9](#Equ9){ref-type=""} and [10](#Equ10){ref-type=""}) are much higher than the total concentration of the receptor, so no change of that quantities will be detected when reaching the thermodynamic equilibrium. Equation ([11](#Equ11){ref-type=""}) results from the law of conservation of matter referring to the receptor.$$\documentclass[12pt]{minimal}
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The solution of the equations [1](#Equ1){ref-type=""}, [2](#Equ2){ref-type=""}, [3](#Equ3){ref-type=""}, [4](#Equ4){ref-type=""}, [5](#Equ5){ref-type=""}, [6](#Equ6){ref-type=""}, [7](#Equ7){ref-type=""}, [8](#Equ8){ref-type=""}, [9](#Equ9){ref-type=""}, [10](#Equ10){ref-type=""} and [11](#Equ11){ref-type=""} with respect to the concentration terms was calculated using the software package MAPLE 11.0 (Maplesoft Waterloo Maple Inc. 1981-2007). Maple is a computer algebra system, allowing users to define mathematical equations in a simple manner, solve these equations with one command line and plot the corresponding results. To elucidate this, the definition of equations ([1](#Equ1){ref-type=""}, [2](#Equ2){ref-type=""}, [3](#Equ3){ref-type=""}, [4](#Equ4){ref-type=""}, [5](#Equ5){ref-type=""}, [6](#Equ6){ref-type=""}, [7](#Equ7){ref-type=""}, [8](#Equ8){ref-type=""}, [9](#Equ9){ref-type=""}, [10](#Equ10){ref-type=""} and [11](#Equ11){ref-type=""}) (see the following command lines e1 to e11) and their solution with the help of the command "solve" (see command line e12) is shown, using the Maple syntax:\> e1:=K0 = RS/R:\> e2:=K1 = AR/(A0\*R):\> e3:=K2 = ARS/(A0\*RS):\> e4:=K3 = ARR/AR:\> e5:=K4 = BR/(B0\*R):\> e6:=K5 = BRS/(B0\*RS):\> e7:=K6 = BRR/(B0\*ARR):\> e8:=K7 = CR/(C0\*R):\> e9:=K8 = CRS/(C0\*RS):\> e10:=K9 = CRR/(C0\*ARR):\> e11:=R0 = R + RS + AR + ARS + ARR + BR + BRS + BRR + CR + CRS + CRR:\> e12:=solve({e1,e2,e3,e4,e5,e6,e7,e8,e9,e10,e11},{R,RS,AR,ARS,ARR,BR,BRS,BRR,CR,CRS,CRR});

The last command led to the following expressions for the concentration terms (Maple notation in brackets) *R* (R), *R\** (RS), *A*^*ortho*^*R* (AR), *A*^*ortho*^*R\** (ARS), *A*^*allo*^*R* (ARR), *BR* (BR), *BR\** (BRS), *BA*^*allo*^*R* (BRR), *CR* (CR), *CR\** (CRS) and *CA*^*allo*^*R* (CRR):

The denominator *d* of the following terms reads as:$$\documentclass[12pt]{minimal}
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Description of the efficacy {#Sec4}
---------------------------

The efficacy determined by steady-state GTPase assay is assumed to be proportional (described by factor *f*, assuming that *f* is independent of any concentration) to all complexes containing an active receptor configuration (equation [24](#Equ24){ref-type=""}):$$\documentclass[12pt]{minimal}
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To introduce the constants *K*~*0*~ to *K*~*9*~ in equation [24](#Equ24){ref-type=""}, the equations [14](#Equ14){ref-type=""}, [16](#Equ16){ref-type=""}, [19](#Equ19){ref-type=""} and [22](#Equ22){ref-type=""} can be introduced into [24](#Equ24){ref-type=""}, leading to the following equation [25](#Equ25){ref-type=""}:$$\documentclass[12pt]{minimal}
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The application of the present mathematical concept onto experimental data values requires to define a reference value *E*~*ref*~ of the effect *E*: *E*~*ref*~ (equation [26](#Equ26){ref-type=""}) represents the effect at *A*~*0*~ = *B*~*0*~ = 0 and *C*~*0*~^*ref*^ = 10 μM and is obtained from equation [25](#Equ25){ref-type=""}:$$\documentclass[12pt]{minimal}
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The resulting relative quantity *E*~*rel*~ (equation [27](#Equ27){ref-type=""}) corresponds directly to the experimental data (Schnell and Seifert [@CR36]) shown in Figure [1](#Fig1){ref-type="fig"}.$$\documentclass[12pt]{minimal}
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Thus, if only thioperamide (B) and sodium ions (A) are present, equation [27](#Equ27){ref-type=""} can be written as$$\documentclass[12pt]{minimal}
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Least-square fit to obtain the constants *K*~*x*~ {#Sec5}
-------------------------------------------------

To determine the constants *K*~*x*~ (*K*~*0*~ to *K*~*9*~) the software MAPLE 11.0 was used. For fitting of the experimental data (Schnell and Seifert [@CR36]), equation [27](#Equ27){ref-type=""} was used, where the constants *K*~*x*~ were substituted by *K*~*x*~  *= 10*^*pKx*^. The least-square fit is based on the following equation [30](#Equ30){ref-type=""}, describing the deviance s^2^:$$\documentclass[12pt]{minimal}
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Construction of the inactive model of hH~3~R {#Sec6}
--------------------------------------------

For the construction of the homology model of the inactive hH~3~R, the crystal structure of the inactive hH~1~R (3RZE) (Shimamura et al. [@CR44]) was used as a template. The hH~3~R homology model was designed using SYBYL 7.0 (Tripos; <http://www.tripos.com>) according to a protocol, described previously (Strasser and Wittmann [@CR46]; Darras et al. [@CR6]; Wagner et al. [@CR50]). Briefly, the artificial lysozyme in 3RZE was deleted and the homology model was generated according to a hH~1~R-hH~3~R amino acid alignment already described (Strasser et al. [@CR48]). The N-terminus, missing in the crystal structure of hH~1~R, was completed using SYBYL 7.0 (Tripos Inc), as described previously (Darras et al. [@CR6]; Wagner et al. [@CR50]). Furthermore, the E2-loop was completed using the "Loop-Search" module of SYBYL 7.0, as described previously for the hH~4~R (Darras et al. [@CR6]; Wagner et al. [@CR50]). Because there is no information about the conformation of the long I3-loop of the hH~3~R, containing more than 100 amino acids, the amino acids Ala^239^ to Arg^347^ were not included into the model. However, to close the resulting gap between TM V and TM VI on the intracellular side, eight alanines were inserted instead. It was shown previously, that internal water molecules play an important role in stabilization or activation of aminergic GPCRs (Angel et al. [@CR1]; Liu et al. [@CR21]). Therefore, the internal water molecules, described in literature were included according to the corresponding crystal structures (Angel et al. [@CR1]; Liu et al. [@CR21]). In a first model, thioperamide was docked manually into the binding pocket of hH~3~R, in such manner that the positively charged imidazole moiety interacts electrostatically with the highly conserved Asp^3.32^, according to the binding mode for analogue compounds, already described in literature (Schnell and Seifert [@CR36]). The remaining part of thioperamide was embedded in a pocket between TM III, TM V and TM VI, as already described for similar H~3~ receptor ligands (Schlegel et al. [@CR33]; Schnell and Seifert [@CR36]). In a second model, one sodium ion was docked manually into the allosteric binding site of hH~3~R, according to the crystal structure of the A~2A~ with a Na^+^ in the allosteric binding site (Liu et al. [@CR21]). Furthermore, a third model, containing thioperamide in the orthosteric and one sodium ion in the allosteric binding site was constructed, as described above for the thioperamide- and the sodium-ion- model. The resulting complexes were minimized energetically with SYBYL 7.0. Subsequently the minimized hH~3~R-models containing thioperamide and/or a sodium ion were embedded in a POPC lipid bilayer. Afterwards, intracellular and extracellular water molecules were added. To achieve electroneutrality, an appropriate number of sodium ions and chloride ions were added into the simulation box. Subsequently, MD simulations were performed with GROMACS 4.0.2 (<http://www.gromacs.org>) as already described (Strasser et al. [@CR47]; Igel et al. [@CR12]; Darras et al. [@CR6]). The parameterization for thioperamide was obtained from the PRODRG server (<http://davapc1.bioch.dundee.ac.uk/prodrg/>). However, the partial charges were adopted by the Gasteiger-Hückel partial charged, calculated with SYBYL 7.0. The force field parameters for the POPC lipids were obtained from the online source <http://moose.bio.ucalgary.ca/index.php?page=Structures_and_Topologies>. For equilibration, a 5 ns MD simulation was performed: Within the first 2.5 ns, force constants of 250 kJ/(mol nm^2^) were put onto the backbone atoms of the TM domains of hH~3~R, within the second 2.5 ns, these force constants were reduced to 100 kJ/(mol nm^2^). Subsequently, 10 ns up to 35 ns productive phase of simulations were performed, without using any force constants.

Results {#Sec7}
=======

Constants *K*~*0*~ to *K*~*9*~ for the hH~3~R, determined by steady-state GTPase assays {#Sec8}
---------------------------------------------------------------------------------------

The nonlinear least square fit was used to determine the constants *K*~*0*~ to *K*~*9*~ (*K*~*x*~), expressed as the corresponding values *pK*~*0*~ -- *pK*~*9*~ (*pK*~*x*~) , using the definition *K*~*x*~  *= 10*^*pKx*^, as described under [Materials and Methods](#Sec2){ref-type="sec"} (Table [1](#Tab1){ref-type="table"}).Table 1**pK** ~**x**~ **, K** ~**x**~ **and Δ** ~**R**~ **G** ^**o**^ **values, describing the constitutive activity, the binding of sodium ions, of thioperamide and histamine to hH** ~**3**~ **Rx*pK*** ~***x***~  **± S.E.M.*K*** ~***x***~  **± S.E.M.*Δ*** ~***R***~ ***G*** ^***o***^ **\[kJ/mol\]**Constitutive activity0*R* ⇌ *R\**-0.04 ± 0.010.92 ± 0.030.21 ± 0.08NaCl (≡A)1*A* + *R* ⇌ *A* ^*ortho*^ *R*0.31 ± 0.032.08 ± 0.20-1.76 ± 0.202*A* + *R\** ⇌ *A* ^*ortho*^ *R\**0.06 ± 0.081.29 ± 0.22-0.33 ± 0.473*A* ^*ortho*^ *R* ⇌ *A* ^*allo*^ *R*1.07 ± 0.0411.98 ± 0.84-6.10 ± 0.21THIO (≡B)4*B* + *R* ⇌ *BR*7.40 ± 0.032.56 · 10^7^ ± 1.35 · 10^6^-42.25 ± 0.155*B* + *R\** ⇌ *BR* ^*\**^7.01 ± 0.031.03 · 10^7^ ± 6.15 · 10^5^-39.98 ± 0.176*B* + *A* ^*allo*^ *R* ⇌ *BA* ^*allo*^ *R*7.23 ± 0.031.71 · 10^7^ ± 9.96 · 10^5^-41.25 ± 0.15HIS (≡C)7*C* + *R* ⇌ *CR*7.48 ± 0.013.05 · 10^7^ ± 1.07 · 10^6^-42.71 ± 0.088*C* + *R\** ⇌ *CR* ^*\**^7.86 ± 0.017.20 · 10^7^ ± 1.71 · 10^6^-44.84 ± 0.069*C* + *A* ^*allo*^ *R* ⇌ *CA* ^*allo*^ *R*6.98 ± 0.019.48 · 10^6^ ± 3.02 · 10^5^-39.81 ± 0.08The data were obtained by a least-square fit of experimental data (Schnell and Seifert [@CR36]), as described under [Materials and Methods](#Sec2){ref-type="sec"}.

The constant *K*~*0*~, describing the constitutive activity has a value of 0.92. Thus, the active hH~3~R (*R\**) is decreased in stability of *Δ*~*R*~*G*^*o*^ = 0.21 kJ/mol compared to the inactive hH~3~R (*R*) (Table [1](#Tab1){ref-type="table"}) according to *R* ⇌ *R\**.

The binding of a sodium ion from the aqueous extracellular side into the allosteric binding site can be divided into two steps, according to the equations [2](#Equ2){ref-type=""} and [4](#Equ4){ref-type=""}. The binding of the Na^+^ into the orthosteric binding site (*A*^*ortho*^*R*) according to *A* + *R* ⇌ *A*^*ortho*^*R* with an association constant *K*~*1*~ of 2.08 is energetically favoured (*Δ*~*R*~*G*^*o*^ = -1.76 kJ/mol) (Table [1](#Tab1){ref-type="table"}). The subsequent binding of the sodium ion from the orthosteric into the allosteric binding site, with a *K*~*3*~ of 11.98, according to *A*^*ortho*^*R* ⇌ *A*^*allo*^*R*, is energetically favoured with *Δ*~*R*~*G*^*o*^ = -6.10 kJ/mol (Table [1](#Tab1){ref-type="table"}). Thus, the consecutive binding process of the sodium ion into its allosteric binding site, according to *A* + *R* ⇌ *A*^*ortho*^*R*, is energetically favoured with *Δ*~*R*~*G*^*o*^ = -7.86 kJ/mol. The binding of a sodium ion into the orthosteric binding site of the active hH~3~R, according to *A* + *R\** ⇌ *A*^*ortho*^*R\**, with *Δ*~*R*~*G*^*o*^ = -0.33 kJ/mol does not differ significantly from zero (Table [1](#Tab1){ref-type="table"}).

The binding of thioperamide to the orthosteric binding site of hH~3~R in absence of a sodium ion in the allosteric binding site is preferred compared to the binding in presence of a sodium ion in the allosteric binding site, as indicated by the corresponding association constants *K*~*4*~, according to *B* + *R* ⇌ *BR*, and *K*~*6*~, according to *B* + *A*^*allo*^*R* ⇌ *BA*^*allo*^*R*. The association constant *K*~*5*~ for the binding of thioperamide to the active state hH~3~R, according to *B* + *R\** ⇌ *BR*^*\**^ is smaller than *K*~*4*~ or *K*~*6*~ (Table [1](#Tab1){ref-type="table"}), which is in good accordance to the experimental findings that thioperamide acts as an inverse agonist at hH~3~R (Schnell and Seifert [@CR36]).

To explain the different amounts of *BR* and *BA*^*allo*^*R* Figure [2](#Fig2){ref-type="fig"} represents the Gibbs energy (*Δ*~*R*~*G*^*o*^) profile for the processes *A + B + R ⇌ A + BR* and *B + A*^*allo*^*R⇌ BA*^*allo*^*R*. The quantity *Δ*~*R*~*G*^*o*^ for the latter process is disfavoured compared to the first one. Nevertheless, the concentration of the complex *BA*^*allo*^R is higher than that of the complex *BR*. The reason for this fact are the two preceding processes *A + B + R ⇌ B + A*^*ortho*^*R* and B + *A*^*ortho*^*R ⇌ B + A*^*allo*^*R* resulting in a stabilization of the complex *BA*^*allo*^*R*, representing thioperamide in the inactive hH~3~R with Na^+^ present in its allosteric binding site (Figure [2](#Fig2){ref-type="fig"}).Figure 2**Gibbs energies (Δ** ~**R**~ **G** ^**O**^ **) according to the constants K** ~**x**~ **, obtained by fitting experimental data.** Schematic Gibbs energy (*Δ* ~*R*~ *G* ^*O*^) profile for the processes *A + B + R ⇌ A + BR* (left branch) and *A + B + R ⇌* B + *A* ^*ortho*^ *R ⇌ B + A* ^*allo*^ *R ⇌ BA* ^*allo*^ *R* (right branch) based on the experimentally determined *K* ~*x*~ values (Table [1](#Tab1){ref-type="table"}).

The association constant *K*~*8*~ of the endogenous agonist histamine to the active hH~3~R, according to *C* + *R\** ⇌ *CR*^*\**^, is higher than for the binding to the inactive hH~3~R in absence (*K*~*7*~) or presence (*K*~*9*~) of a sodium ion in the allosteric binding site (Table [1](#Tab1){ref-type="table"}). This is in good accordance to the experimental findings revealing histamine as an agonist at hH~3~R (Schnell and Seifert [@CR36]).

Relative concentration profiles of different receptor complexes in dependence of thioperamide, histamine and NaCl in the steady-state GTPase assay at hH~3~R {#Sec9}
------------------------------------------------------------------------------------------------------------------------------------------------------------

The relative concentration profiles (Figure [3](#Fig3){ref-type="fig"}) of the different species mentioned above, as function of concentrations of thioperamide, histamine and sodium chloride were calculated based on the association constants, given in Table [1](#Tab1){ref-type="table"}. In absence or presence of 100 mM NaCl, the amount of the ligand- and Na^+^-free receptor states *R\** and *R* decreases to zero with increasing concentration of thioperamide (Figure [3](#Fig3){ref-type="fig"}). The amount of *BR* (inactive thioperamide-hH~3~R-complex without Na^+^) and *BR\** (active thioperamide-hH~3~R-complex without Na^+^) increases in absence of sodium chloride with increasing concentration of thioperamide. However, the concentration of *BR\** is smaller than of *BR*, which is in good accordance to the experimental findings that thioperamide is an inverse agonist (Schnell and Seifert [@CR36]). Based on these data it has to be suggested that thioperamide binds not only to the inactive hH~3~R but also to the active state hH~3~R (Table [1](#Tab1){ref-type="table"}). Consequently, thioperamide has to be defined as a partial inverse agonist. To support these results, analogous calculations, but without including equation [6](#Equ6){ref-type=""} and related variables were not able to fit the experimental data. With increasing concentrations of sodium chloride, the amount of *BA*^*allo*^*R* increases, whereas the amount of *BR* decreases. At a concentration of about 62 mM, the relative concentrations of *BR* and *BA*^*allo*^*R* are identical. Thus, at concentrations of sodium chloride \< 62 mM, the relative concentration of *BR* is larger than of *BA*^*allo*^*R*, whereas at concentrations of sodium chloride \> 62 mM, the relative concentration of *BR* is smaller than of *BA*^*allo*^*R*. The latter case is presented for a concentration of sodium chloride of 100 mM in Figure [3](#Fig3){ref-type="fig"}: There, the amount of *BA*^*allo*^*R* is about factor 1.5 higher than the amount of *BR*.Figure 3**Concentration profiles of different Na** ^**+**^ **- or ligand-hH** ~**3**~ **R complexes in absence or presence of NaCl.** The concentration profiles were calculated according to the equations [13](#Equ13){ref-type=""}, [14](#Equ14){ref-type=""}, [15](#Equ15){ref-type=""}, [16](#Equ16){ref-type=""}, [17](#Equ17){ref-type=""}, [18](#Equ18){ref-type=""}, [19](#Equ19){ref-type=""}, [20](#Equ20){ref-type=""}, [21](#Equ21){ref-type=""}, [22](#Equ22){ref-type=""} and [23](#Equ23){ref-type=""}, using the constants *K* ~*x*~ (Table [1](#Tab1){ref-type="table"}), obtained by fitting of the experimental data of Schnell and Seifert [@CR36], shown in Figure [1](#Fig1){ref-type="fig"}, as described in [Materials and Methods](#Sec2){ref-type="sec"}.

In absence or presence of 100 mM NaCl, the amount of the ligand- and Na^+^-free receptor states *R\** and *R* decreases to zero with increasing concentrations of histamine whereas the amount of *CR\** increases (Figure [3](#Fig3){ref-type="fig"}). However, regardless of the sodium chloride concentration, a small amount of the Na^+^-free inactive histamine-hH~3~R-complex (*CR*) is present. With increasing concentration of sodium chloride, the amount of *CA*^*allo*^*R* increases. At a concentration of about 285 mM of NaCl, the concentrations of *CR\** and *CA*^*allo*^*R* are nearly equal. For all concentrations of sodium chloride less than 285 mM, *CR\** is higher than *CA*^*allo*^*R* (Figure [3](#Fig3){ref-type="fig"}). Based on these data it has to be suggested that histamine binds also in the inactive state hH~3~R with or without Na^+^ bound in its allosteric binding site. However, histamine is defined as a full agonist, because there is no other ligand with higher stimulatory effect than histamine at hH~3~R. To support these results, analogue calculations, but without including equations [8](#Equ8){ref-type=""} and/or [10](#Equ10){ref-type=""} and related variables were performed, but were not able to fit the experimental data. However, in presence of 100 mM NaCl, the concentration of *CR\** is about 3 times higher than that of *CA*^*allo*^*R* (Figure [3](#Fig3){ref-type="fig"}).

Explanation of the steady-state GTPase results for the hH~3~R {#Sec10}
-------------------------------------------------------------

In general, it is suggested that only active hH~3~R complexes induce GTPase activity. Thus, to explain the results of the steady-state GTPase assay at hH~3~R, the complexes *R\**, *A*^*ortho*^*R\** and *BR\** in case of thioperamide and *R\**, *A*^*ortho*^*R\** and *CR\** in case of histamine have to be considered. The sum of these values results in the experimentally determined course of GTPase activity (Figures [4](#Fig4){ref-type="fig"} and [5](#Fig5){ref-type="fig"}). Figure [4](#Fig4){ref-type="fig"} shows that the experimentally observed courses within the steady-state GTPase assay for thioperamide or histamine in absence or presence of 100 mM NaCl at hH~3~R, are the sum of at least two different courses, namely *R\** and *BR\** (in case of thioperamide) and *R\** and *CR\** (in case of histamine). The third complex, *A*^*ortho*^*R\**, is zero in absence of NaCl or nearly zero in presence of 100 mM NaCl. The data for thioperamide (Figure [4](#Fig4){ref-type="fig"}) show that the contribution of R\* to the GTPase activity decreases with increasing thioperamide concentration. In contrast, the contribution of the active thioperamide-hH~3~R-complexes (*BR\**) to the GTPase activity increases (Figure [4](#Fig4){ref-type="fig"}). But because the increase of *BR\** is not as strong as the decrease of *R\**, the final GTPase activity is decreased with increasing thioperamide concentration, which is in very good accordance to experimental results (Schnell and Seifert [@CR36]). The data for histamine (Figure [4](#Fig4){ref-type="fig"}) show that the contribution of R\* to the GTPase activity decreases with increasing histamine concentration. In contrast, the contribution of the active histamine-hH~3~R-complexes (*CR\**) to the GTPase activity increases (Figure [4](#Fig4){ref-type="fig"}). Because the increase of *CR\** is stronger, as the decrease of *R\**, the final GTPase activity is increased with increasing histamine concentration, which is in very good accordance to experimental results (Schnell and Seifert [@CR36]). As provided by Figure [5](#Fig5){ref-type="fig"}, the calculated course of basal GTPase activity or GTPase activity in presence of 10 μM histamine or thioperamide in dependence of NaCl concentration is in very good accordance to the experimental data.Figure 4**Portion of** ***R\**** **,** ***A*** ^***ortho***^ ***R\**** **and** ***BR\**** **or** ***CR\**** **, in dependence of ligand concentration in GTP hydrolysis and the resulting steady-state GTPase course.** The profiles were calculated according to the equations [14](#Equ14){ref-type=""}, [16](#Equ16){ref-type=""}, [19](#Equ19){ref-type=""}, [23](#Equ23){ref-type=""}, [24](#Equ24){ref-type=""} and [26](#Equ26){ref-type=""} using the constants *K* ~*x*~ (Table [1](#Tab1){ref-type="table"}), obtained by fitting of the experimental data of Schnell and Seifert [@CR36], shown in Figure [1](#Fig1){ref-type="fig"}, as described in [Materials and Methods](#Sec2){ref-type="sec"}.Figure 5**Portion of** ***R\**** **,** ***A*** ^***ortho***^ ***R\**** **and** ***BR\**** **or** ***CR\**** **, in dependence of NaCl concentration in GTP hydrolysis and the resulting steady-state GTPase course.** The profiles were calculated according to equation [27](#Equ27){ref-type=""} using the constants *K* ~*x*~ (Table [1](#Tab1){ref-type="table"}), obtained by fitting of the experimental data of Schnell and Seifert [@CR36], shown in Figure [1](#Fig1){ref-type="fig"}, as described in [Materials and Methods](#Sec2){ref-type="sec"}.

Calculation of the *pEC*~*50*~ values {#Sec11}
-------------------------------------

Additionally, it is possible to deduce an equation for the experimentally observed *pEC*~*50*~ value from the equations ([28](#Equ28){ref-type=""} and [29](#Equ29){ref-type=""}) for thioperamide in dependence of the sodium ion concentration *A*~*0*~:$$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ pE{C}_{50}=- \log \left(\frac{1+{K}_0+{A}_0\left({K}_1+{K}_0{K}_2+{K}_1{K}_3\right)}{K_4+{K}_0{K}_5+{A}_0{K}_1{K}_3{K}_6}\right) $$\end{document}$$and analogously for histamine:$$\documentclass[12pt]{minimal}
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These equations show that the *pEC*~*50*~ value is dependent of the amount of constitutive activity, described by *K*~*0*~ as well as of the constants *K*~*1*~, *K*~*2*~ and *K*~*3*~, describing the three different equilibria between sodium ions and the receptor (equations [2](#Equ2){ref-type=""}, [3](#Equ3){ref-type=""}, [4](#Equ4){ref-type=""}), and the concentration of sodium ion *A*~*0*~ itself. Furthermore, the ligand specific constants (thioperamide: *K*~*4*~, *K*~*5*~ and *K*~*6*~; histamine: *K*~*7*~, *K*~*8*~ and *K*~*9*~) have an influence onto the *pEC*~*50*~. The equations show that the *pEC*~*50*~ increases with increase of the ligand-receptor specific constants *K*~*4*~, *K*~*5*~, *K*~*6*~ (thioperamide) or *K*~*7*~, *K*~*8*~, *K*~*9*~ (histamine). Furthermore, the *pEC*~*50*~ increases with decreasing *K*~*2*~. If no sodium chloride is present, the constants *K*~*1*~, *K*~*2*~, *K*~*3*~, *K*~*6*~ (thioperamide) and *K*~*9*~ (histamine) are not relevant. Because of the complexity of the equations [31](#Equ31){ref-type=""} and [32](#Equ32){ref-type=""}, the influence of *K*~*0*~, *K*~*1*~, *K*~*3*~ and *A*~*0*~ onto the *pEC*~*50*~ depends on the values of the other variables in the equations, and thus, no simple rules to describe the influence of each *K*~*x*~ onto *pEC*~*50*~ can be presented.

Using the *K*~*x*~ values, obtained by the fit of the experimental data (Table [1](#Tab1){ref-type="table"}), for the GTPase curve of thioperamide in absence of NaCl, a *pEC*~*50*~ of 7.26 and in presence of 100 mM NaCl, a *pEC*~*50*~ of 7.21 was obtained. The *pEC*~*50*~ value in absence of sodium chloride fits well to the experimental data (7.15 ± 0.31 (Schnell and Seifert [@CR36])). The calculated *pEC*~*50*~ value in presence of 100 mM NaCl does not differ within the limits of error from the experimental data (7.43 ± 0.28 (Schnell and Seifert [@CR36])). Using the *K*~*x*~ values, obtained by the fit of the experimental data (Table [1](#Tab1){ref-type="table"}), for the GTPase curve of histamine in absence of NaCl, a *pEC*~*50*~ of 7.70 and in presence of 100 mM NaCl, a *pEC*~*50*~ of 7.41 was obtained. The *pEC*~*50*~ value in absence (exp.: 8.01 ± 0.39 (Schnell and Seifert [@CR36])) and presence (exp.: 7.53 ± 0.18 (Schnell and Seifert [@CR36])) of sodium chloride fit well to the experimental data.

Molecular dynamics of different thioperamide- and Na^+^-hH~3~R-complexes {#Sec12}
------------------------------------------------------------------------

In order to study the influence of a sodium ion in its allosteric binding site onto the conformation of the ligand-free inactive hH~3~R, two different MD simulations were performed: On the one hand, one Na^+^ was placed into its allosteric site, according to the crystal structures of the A~2A~ (Liu et al. [@CR21]). For purpose of reference, an identical system, except with the Na^+^ not located in the allosteric binding site of the hH~3~R, but somewhere in the aqueous extracellular part of the simulation box was built. The MD simulations, performed under comparable conditions, revealed a stabilization of the inactive conformation of the hH~3~R, with the sodium ion being stable in its allosteric binding site. In contrast for the reference system, without a Na^+^ in the allosteric pocket of hH~3~R, after \~ 6 ns of simulation, the hH~3~R started to undergo a conformational change especially in the intracellular part of the receptor. Here, a slight outward movement of TM VI was observed. Thus, the findings of the MD simulations support the experimental findings that a sodium ion, bound in its allosteric binding site stabilizes the inactive conformation of hH~3~R.

In order to study the influence of a sodium ion in its allosteric binding site onto the binding mode of thioperamide in its orthosteric binding site, two different MD simulations were performed: On the one hand, one Na^+^ was placed into its allosteric site and one thioperamide was placed into its orthosteric binding pocket. On the other hand, one thioperamide was put into its orthosteric binding site, whereas no Na^+^ was located in the allosteric binding site. The MD simulations, performed under comparable conditions, revealed two different binding modes of thioperamide. In presence of a Na^+^ in the allosteric binding site, the imidazole moiety is located "above" the highly conserved Asp^3.32^ (Figure [6](#Fig6){ref-type="fig"}A) and the sodium ion remains stable in its allosteric site (Figure [6](#Fig6){ref-type="fig"}A). In contrast, in absence of the Na^+^ in the allosteric site, the imidazole moiety of thioperamide is located below the highly conserved Asp^3.32^, in direction to the highly conserved Asp^2.50^ (Figure [6](#Fig6){ref-type="fig"}B). As a consequence of the missing compensation of the negative charge of Asp^2.50^ by a sodium ion, the positively charged imidazole moiety of thioperamide is attracted by Asp^2.50^. However, in both cases, the thioperamide remains stable in its orthosteric binding pocket.Figure 6**Binding mode of thioperamide to the orthosteric binding site of hH** ~**3**~ **R. A**, in presence of a sodium ion in the allosteric binding site. Yellow circle: interaction of the imidazole moiety of thioperamide with the highly conserved Asp^3.32^; orange circle: a sodium ion in its allosteric binding site, interacting with Ser^3.39^ and Asp^2.50^ **B**, in absence of a sodium ion in the allosteric binding site. Yellow circle: interaction of the imidazole moiety of thioperamide with the highly conserved Asp^3.32^, but compared to A) located downwards in direction to Asp^2.50^. Shown are snapshots after 5 ns of productive MD simulation.

An analysis of the fluctuation of the sodium ion in the allosteric binding site in absence (Figure [7](#Fig7){ref-type="fig"}A) and presence (Figure [7](#Fig7){ref-type="fig"}B) of thioperamide in the orthosteric binding site is presented. In case that there is no ligand in the orthosteric binding pocket, the sodium ion shows a strong fluctuation between the Asp^2.50^ of the allosteric and Asp^3.32^ of the orthosteric site (Figure [7](#Fig7){ref-type="fig"}A). In case that the distance of the Na^+^ is with about 0.25 nm smallest to one of the carboxy oxygens (OD1 or OD2) of Asp^2.50^, the distance to one of the carboxy oxygens (OD1 or OD2) of Asp^3.32^ is about 0.87 nm (Figure [7](#Fig7){ref-type="fig"}A). In the other case, a distance of the Na^+^ to the Asp^2.50^ of about 0.4 nm was observed, whereas the distance of the Na^+^ to the Asp^3.32^ decreased to about 0.65 nm (Figure [7](#Fig7){ref-type="fig"}A). In the absence of a ligand, the sodium ion switches its position with a water molecule in the sodium binding channel. In contrast, if thioperamide is bound to the orthosteric binding site, the sodium ion remains very stable near to Asp^2.50^ and does not fluctuate between Asp^2.50^ and Asp^3.32^ (Figure [7](#Fig7){ref-type="fig"}B). Thus, the modelling data indicate that thioperamide in the orthosteric and Na^+^ in the allosteric site have a mutual influence to each other.Figure 7**Distance of the Na** ^**+**^ **in the allosteric binding site to Asp** ^**2.50**^ **and Asp** ^**3.32**^ **.** Shown are the data of representative 5 ns of MD simulation.

An analysis of the positions of the chloride ions, present in the simulation box, during the simulation revealed no uniform distribution over the whole aqueous phase. Instead, a higher probability of chloride ions between the TM domains of the intracellular part of the hH~3~R relative to the remaining aqueous phase was observed (Figure [8](#Fig8){ref-type="fig"}). Although the increased probability of a chloride ion between the intracellular part of the TMs, a stable binding of one and the same Cl^-^ during more than 300 ps of the simulation was not observed. Because the intracellular part of the receptor is the target for the C-terminus of the Gα subunit, this observation may indicate that anions may have an influence onto the Gα-binding process and therefore onto GTP hydrolysis.Figure 8**Cl** ^**-**^ **binding site between the TM domains of the intracellular part of the hH** ~**3**~ **R.** Shown are the positions of chloride ions (green spheres) accumulated over the whole simulation time.

Discussion {#Sec13}
==========

The results obtained in this study suggest that thioperamide, known as inverse agonist, not only binds into the inactive state hH~3~R, but also into the active hH~3~R. However, as suggested by the corresponding association constants, the binding of thioperamide to the inactive hH~3~R is preferred, compared to the binding to the active hH~3~R. Furthermore, the present results indicate that histamine, known as an agonist, not only binds to the active state hH~3~R, but also to the inactive hH~3~R. But as suggested by the corresponding association constants, the binding of histamine to the active hH~3~R is preferred, compared to the binding to the inactive hH~3~R. Thus, this kind of data analysis presented in this study allows to obtain information about association constants of a ligand to the inactive and active state of a GPCR separately.

In literature, the influence of different cations and anions onto the signalling of various GPCRs is discussed (Schetz and Sibley [@CR32]; Swaminath et al [@CR49]; Seifert and Wenzel-Seifert [@CR39]; Schnell and Seifert [@CR36]). At hH~3~R, the GTP hydrolysis in presence of 10 μM histamine or 10 μM thioperamide or the basal GTP hydrolysis without presence of a ligand was analyzed in dependence of the concentration of different monovalent salts, like LiCl, LiBr, LiJ, NaCl, NaBr, NaJ, KCl, KBr and KJ (Schnell and Seifert [@CR36]). These data indicate that not only cations have an influence onto GPCR signalling, but also anions. Within the MD simulations at hH~3~R, chloride ions were observed more frequently at the intracellular side of the receptor. This is in very good accordance to the fact that, compared to the extracellular side of the hH~3~R, more positively charged amino acids are located at the intracellular side of the receptor. Although we could not detect a stable binding of the same chloride at the intracellular part of hH~3~R over several ns, we observed chloride ions binding for about 300 ps to positively charged amino acids of the hH~3~R, e.g. Arg^3.50^ (Figure [8](#Fig8){ref-type="fig"}), for several times during the whole simulation. This "sporadic" binding of a chloride ion may hinder the G protein to bind onto the active state hH~3~R, leading to a decreased basal activity with increasing concentration of chloride or other ions. Additionally, an effect of anions directly onto the G protein has to be considered (Higashijima et al. [@CR10]). Relevant anion binding sites at G proteins can be identified within future studies by crystal structures or MD simulations. However, in order to obtain a deeper insight onto the influence of cations and anions onto GPCR signalling, more experimental studies, combined with modelling studies have to be performed. In this context it may be of interest to study the influence of monovalent salts onto the GPCR signalling of hH~4~R in more detail. Although it was shown that the hH~4~R is insensitive to sodium ions (Schneider and Seifert [@CR34]), it may be useful to compare two different receptors, coupling to one and the same G protein in order to be able to separate between an effect of ions onto the receptor or onto the G protein.

In general, functional data, e.g. obtained within the steady-state GTPase assay are analyzed by determination of the *pEC*~*50*~ value of a ligand. However, *pEC*~*50*~ values represent a complex quantity, consisting of distinct ligand- and/or receptor specific contributions, as shown above. Thus, a comprehensive explanation of *pEC*~*50*~ values on a molecular level with the help of computational methods may be a challenge. In contrast, if functional data will be analyzed using the equations mentioned above, distinct equilibrium constants, which can be related to results of molecular modelling studies, can be obtained. For example, using the present equations, it is possible to determine the binding constant for the sodium ion from the extracellular side, via the orthosteric binding site into its allosteric binding site. It may be suggested that there are no significant differences for the binding constant of the sodium ion from the extracellular side into the orthosteric binding pocket, because this process is mainly driven by an electrostatic attraction of the positively charged sodium ion and negatively charged amino acids in the orthosteric binding pocket, like the highly conserved Asp^3.32^. Thus, significant differences in the related constants *K*~*1*~ or *K*~*2*~ between sodium sensitive and sodium insensitive GPCRs are not expected. Of course, the binding of the sodium ion from the orthosteric to the allosteric binding site is also suggested to be driven by an electrostatic attraction between the sodium ion and the highly conserved Asp^2.50^ in the allosteric binding site. However, a comparison of all amino acids, forming the binding channel for the sodium ion from the orthosteric to the allosteric binding site, between the human aminergic GPCRs reveals distinct differences (Figure [9](#Fig9){ref-type="fig"}). Thus, it can be suggested that differences in amino acids between the human aminergic GPCRs within this channel may have a large influence onto sodium sensitivity, and consequently may have influence onto the constant *K*~*3*~, which corresponds to the transition of the sodium ion from its orthosteric to its allosteric binding site. Due to the differences in amino acids in direct neighbourhood to the sodium binding channel (Figure [9](#Fig9){ref-type="fig"}), it will be interesting to perform similar studies, as presented within this work, at other human aminergic GPCRs and to compare the resulting constants *K*~*3*~. This may give a more detailed insight onto the sodium sensitivity of GPCRs on a molecular level. Furthermore, the constants *K*~*6*~ (here describing the binding of thioperamide to the receptor with a sodium ion being in its allosteric binding pocket) and *K*~*9*~ (here describing the binding of histamine to the receptor with a sodium ion being in its allosteric binding pocket) are suggested to have an influence onto the sodium sensitivity of a GPCR. In general, if a sodium ion is bound in its allosteric binding site it has to be taken into account that this may have an influence onto the orthosteric ligand binding pocket, e.g. amino side chains being located in near neighbourhood to the allosteric and orthosteric binding site may change its conformation in dependence of absence or presence of a sodium ion in its allosteric site. Consequently this may have influence onto the binding properties of a ligand to its binding pocket. This hypothesis is supported by the MD simulations of thioperamide in the inactive hH~3~R (Figure [6](#Fig6){ref-type="fig"}). The results suggest that the binding mode of thioperamide is dependent of the absence or presence of a sodium ion in the allosteric pocket.Figure 9**Sodium binding channel of an aminergic GPCR. A**, Na^+^-binding channel of an aminergic GPCR with highly conserved amino acids. **B**, Distribution of amino acids being in direct contact to the sodium binding channel of all human aminergic GPCRs.

Conclusion {#Sec14}
==========

In this study we developed a mathematical model to describe the sensitivity of GPCRs to sodium ions in presence or absence of a ligand. The excellent quality of the new mathematical model, consisting of a couple equilibrium constants, was shown by fitting experimental data obtained with the steady-state GTPase assay at hH~3~R. On the one hand, the new mathematical model allows a more detailed insight onto the ligand- and Na^+^ binding processes to a GPCR on a molecular level. On the other hand, the model may be extended to the quantitative description of arbitrary ligand-ion-receptor-binding processes.
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